U.S. markets closed

Genmab A/S (GMAB)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
31.08+0.65 (+2.14%)
At close: 04:00PM EDT
31.08 0.00 (0.00%)
After hours: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close30.43
Bid27.00 x 900
Ask33.95 x 800
Day's Range30.48 - 31.11
52 Week Range27.42 - 49.07
Avg. Volume671,612
Market Cap20.43B
Beta (5Y Monthly)0.71
PE Ratio (TTM)60.76
EPS (TTM)0.51
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est45.79
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Near Fair Value
7% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for GMAB

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Genmab A/S
    Daily – Vickers Top Buyers & Sellers for 01/19/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    4 months agoArgus Research
View more
  • GlobeNewswire

    Capital Increase in Genmab as a Result of Employee Warrant Exercise

    Company Announcement COPENHAGEN, Denmark; May 17, 2022 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 19,302 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1: 450 shares at DKK 623.50,2,500 shares at DKK 636.50,2,800 shares at DKK 939.50,6,837 shares at DKK 1,025.00,773 sha

  • GlobeNewswire

    Genmab Announces Multiple Abstracts to be Presented at the European Hematology Association (EHA) Annual Congress

    Media Release Copenhagen, Denmark, May 12, 2022 Multiple epcoritamab (DuoBody®-CD3xCD20) studies will be presented showcasing preliminary efficacy and safety findings in a variety of patient populations in need of treatment optionsSeveral abstracts evaluating Genmab owned and partnered programs accepted for presentation Genmab A/S (Nasdaq: GMAB) announced today that multiple abstracts evaluating epcoritamab (DuoBody-CD3xCD20), an investigational subcutaneous bispecific antibody, will be presente

  • GlobeNewswire

    Genmab Announces Financial Results for the First Quarter of 2022

    May 11, 2022 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2022 Highlights DARZALEX® net sales as reported by Johnson & Johnson increased 36% compared to the first three months of 2021 to USD 1,856 million, resulting in royalty revenue of DKK 1,501 millionGenmab updates its 2022 financial guidance “During the first quarter of 2022, there were continued advancements in our pipeline, including the first patient dosed with DuoBody®-CD3xB7H4 (GEN1047), the presentation of